|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
723.09(B) |
Last
Volume: |
3,201,799 |
Avg
Vol: |
3,289,637 |
52
Week Range: |
$390.35 - $792.28 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
435,750 |
871,420 |
2,951,506 |
6,211,418 |
Total Sell Value |
$330,574,311 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
2 |
2 |
5 |
6 |
Total Sell Transactions |
5 |
14 |
46 |
89 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Norton Johna |
EVP, Global Quality |
|
2024-02-12 |
4 |
A |
$737.26 |
$1,229,750 |
D/D |
1,668 |
32,484 |
|
- |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2024-02-12 |
4 |
A |
$737.26 |
$3,953,925 |
D/D |
5,363 |
65,569 |
|
- |
|
Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
|
2024-02-12 |
4 |
A |
$737.26 |
$2,079,810 |
D/D |
2,821 |
29,682 |
|
- |
|
Hakim Anat |
EVP, GC & Secretary |
|
2024-02-12 |
4 |
A |
$737.26 |
$4,287,167 |
D/D |
5,815 |
30,479 |
|
- |
|
Ricks David A |
President, Chair, and CEO |
|
2024-02-12 |
4 |
A |
$737.26 |
$28,304,886 |
D/D |
38,392 |
479,250 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Dia&Obe, LLY USA |
|
2024-02-12 |
4 |
A |
$737.26 |
$3,953,188 |
D/D |
5,362 |
44,583 |
|
- |
|
Skovronsky Daniel |
EVP, CSO & Pres. LRL & LLY Imm |
|
2024-02-12 |
4 |
A |
$737.26 |
$9,518,027 |
D/D |
12,910 |
123,738 |
|
- |
|
Lilly Endowment Inc |
|
|
2024-02-09 |
4 |
S |
$740.27 |
$152,753,428 |
D/D |
(206,257) |
99,118,810 |
|
-5% |
|
Ricks David A |
President, Chair, and CEO |
|
2024-02-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
956 |
440,858 |
|
- |
|
Lilly Endowment Inc |
|
|
2024-02-08 |
4 |
S |
$740.06 |
$6,470,336 |
D/D |
(8,743) |
99,325,067 |
|
-6% |
|
Norton Johna |
EVP, Global Quality |
|
2024-02-01 |
4 |
D |
$645.61 |
$365,415 |
D/D |
(566) |
30,816 |
|
- |
|
Norton Johna |
EVP, Global Quality |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,268 |
31,382 |
|
- |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2024-02-01 |
4 |
D |
$645.61 |
$1,190,505 |
D/D |
(1,844) |
60,206 |
|
- |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,124 |
62,050 |
|
- |
|
Hakim Anat |
EVP, GC & Secretary |
|
2024-02-01 |
4 |
D |
$645.61 |
$1,269,915 |
D/D |
(1,967) |
24,664 |
|
- |
|
Hakim Anat |
EVP, GC & Secretary |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,442 |
26,631 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Dia&Obe, LLY USA |
|
2024-02-01 |
4 |
D |
$645.61 |
$1,190,505 |
D/D |
(1,844) |
39,221 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Dia&Obe, LLY USA |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,124 |
41,065 |
|
- |
|
Van Naarden Jacob |
EVP & Pres., Loxo@Lilly |
|
2024-02-01 |
4 |
D |
$645.61 |
$1,087,853 |
D/D |
(1,685) |
13,778 |
|
- |
|
Van Naarden Jacob |
EVP & Pres., Loxo@Lilly |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,618 |
15,463 |
|
- |
|
Skovronsky Daniel |
EVP, CSO & Pres. LRL & LLY Imm |
|
2024-02-01 |
4 |
D |
$645.61 |
$2,862,635 |
D/D |
(4,434) |
110,828 |
|
- |
|
Skovronsky Daniel |
EVP, CSO & Pres. LRL & LLY Imm |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,941 |
115,262 |
|
- |
|
Ricks David A |
President, Chair, and CEO |
|
2024-02-01 |
4 |
D |
$645.61 |
$8,547,876 |
D/D |
(13,240) |
441,814 |
|
- |
|
Ricks David A |
President, Chair, and CEO |
|
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,611 |
455,054 |
|
- |
|
Yuffa Ilya |
EVP & President, LLY Intl |
|
2024-02-01 |
4 |
D |
$645.61 |
$1,074,295 |
D/D |
(1,664) |
15,012 |
|
- |
|
3297 Records found
|
|
Page 2 of 132 |
|
|